Research from University of Texas MD Anderson Cancer Center Yields New Findings on Neutropenia (A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with...).

The article offers information on a study comparing imipenem/cilastatin/relebactam (IPM/REL) with standard-of-care antibiotics for treating febrile neutropenia in cancer patients. Topics discussed include the efficacy and safety of IPM/REL versus standard antibiotics; the impact of antibiotic resistance; and the potential need for updating current treatment protocols.